Biotech - Spark Newswire

1 minute read

IVERIC bio’s Geographic Atrophy Candidate Shows Significant Reduction In Disease Progression

Today, 10:57 AM

IVERIC bio Inc (NASDAQ:ISEE) announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating the reduction…

ISEE

1 minute read

FDA AdComm Gives Thumbs Up To Pfizer’s RSV Vaccine Candidate For Elderly People

By Vandana Singh

Today, 10:57 AM

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc’s (NYSE:PFE) available data is adequate to…

PFE

1 minute read

FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate

By Vandana Singh

Today, 10:57 AM

The FDA issued a Complete Response Letter to Cytokinetics Incorporated’s (NASDAQ:CYTK) omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for…

CYTK

1 minute read

FDA Approves Regeneron-Sanofi’s Sarilumab As First Biologic For Stiffness, Pain In Muscles

By Vandana Singh

Today, 10:57 AM

The FDA approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval…

REGN

1 minute read

Atyr Pharma’s Efzofitimod Has Received FDA For Systemic Sclerosis (SSc) And Fast Track Designation For SSc-Associated Interstitial Lung Disease (SSc-ILD); Proof-of-concept Study In SSc-ILD Expected To Begin In 2023

By Benzinga Newsdesk

Today, 10:57 AM

The Phase 2 study is expected to be a randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with SSc-ILD. This is expected to be

LIFE

2 minute read

Novavax Ushers New CEO On Uncertainty Concerns, Says It Needs To Work On Competitive COVID-19 Product

By Vandana Singh

Today, 10:57 AM

COVID-19 vaccine maker Novavax Inc (NASDAQ: NVAX) shares plunged after it

NVAX

1 minute read

Novocure Has Enrolled The Final Patient In The Pivotal METIS Study Evaluating The Efficacy Of Tumor Treating Fields (TT Fields) Therapy Following Stereotactic Radiosurgery For Brain Metastases Resulting From Non-small Cell Lung Cancer

By Benzinga Newsdesk

Today, 10:57 AM

Following the completion of enrollment, patients will be followed for a minimum of 12 months.

NVCR

1 minute read

Why Reata Pharma Shares Are Skyrocketing Today

By Vandana Singh

Today, 10:57 AM

The FDA approved Reata Pharmaceuticals Inc’s (NASDAQ:RETA) Skyclarys (omaveloxolone) for Friedreich’s ataxia in adults and adolescents aged 16 and older. With…

RETA

4 minute read

Reported Late Tuesday Feb. 28, Regeneron Pharmaceuticals And Sanofi Announce Kevzara Approved By FDA As First And Only Biologic Indicated For Patients With Polymyalgia Rheumatica

By Happy Mohamed

Today, 10:57 AM

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE,

REGN

1 minute read

Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race

By Vandana Singh

Today, 10:57 AM

Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…

GPCR